La cadena de opciones muestra datos clave de las opciones de acciones de Vimeo a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Vimeo..

Vimeo (NASDAQ:VMEO) Bolsa, Cadena de Opciones

Vimeo

Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. Its comprehensive and cloud-based tools empower its users to create, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.

Vimeo Inc

Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.48 by 2.08 percent. This is a 5.77 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $55.97 million which missed the analyst consensus estimate of $57.54 million by 2.74 percent. This is a 7.50 percent decrease over sales of $60.50 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

CGBD

Carlyle Secured Lending Q3 Adj $0.49 Beats $0.48 Estimate, Sales $55.97M Miss $57.54M Estimate

Guidance

GMED

Globus Medical Sees FY24 Revenue $2.49B-$2.50B Vs $2.481B Est.; Adj. Diluted EPS $2.90-$3.00 Vs $2.85 Est.

WIIM

Limbach Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.20 by 16.67 percent. This is a 19.08 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $513.54 million which missed the analyst consensus estimate of $542.84 million by 5.40 percent. This is a 0.37 percent increase over sales of $511.65 million the same period last year.

Northern Oil & Gas Q3 Adj $1.40 Beats $1.20 Estimate, Sales $513.54M Miss $542.84M Estimate

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

BBAI

BigBear.ai Affirms 2024 Revenue Guidance $165M-$180M

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Vimeo Holdings GAAP EPS of $0.05 beats by $0.04, revenue of $104.56M beats by $5.08M

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – QuinStreet&nbsp;(QNST)&nbsp;u...

Closing Bell Movers: Palantir jumps 13% after results

Vimeo, Inc. (VMEO) Q3 2024 Earnings Call Transcript

Vimeo, Inc. ( ($VMEO) ) has released its Q3 earnings. Here is a breakdown of the information Vimeo, Inc. presented to its investors. Vimeo, Inc. is...

Vimeo Reports Strong Enterprise Growth and Revenue Stability

Piper Sandler analyst Thomas Champion reiterated a Hold rating on Vimeo (VMEO – Research Report) today and set a price target of $7.00. The company...

Piper Sandler Sticks to Their Hold Rating for Vimeo (VMEO)

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Sensata (ST – Research Report), Vimeo (VMEO – Rese...

Analysts Offer Insights on Technology Companies: Sensata (ST), Vimeo (VMEO) and Flex (FLEX)

TD Cowen raised the firm's price target on Vimeo (VMEO) to $7 from $6 and keeps a Hold rating on the shares. The firm said its 3Q24 revenue and EBI...

Vimeo price target raised to $7 from $6 at TD Cowen

Truist raised the firm's price target on Vimeo (VMEO) to $9 from $7 and keeps a Buy rating on the shares. The company's Q3 results and Q4 guide cam...

Vimeo price target raised to $9 from $7 at Truist

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Boeing's (BA) machinist union ha...

Boeing union to end strike, Palantir reports Q3 beat: Morning Buzz

Vimeo posts profit and revenue beat in Q3, paints picture for growth ahead; shares rise

AAPL

ALAB

ATUS

AZPN

BOOM

BOWL

BWIN

CRRFY

CRUS

CVNA

DLTR

EBAY

EGHT

EVER

FANG

FLEX

FWRD

GKOS

HDSN

HIMS

HOLX

ILMN

JELD

LSCC

NFLX

NXPI

PAYO

PLTR

QNST

REAL

SLAB

TCMD

UBER

VMEO

VRTX

WYNN

Press Releases

Vimeo Q1 2024 Shareholder Letter Available on Company's IR Site

Vimeo to Report Q2 2024 Earnings and Host Earnings Video Event on August 5, 2024

Vimeo Announces AI-Powered Video Translation with Authentic Voice Cloning

Vimeo Q2 2024 Shareholder Letter Available on Company's IR Site

Management

Vimeo Appoints Robert Petrocelli as Company's First Chief Product & Technology Officer

Vimeo Appoints Enterprise Software Veteran Charlie Ungashick to Drive Innovation as Chief Marketing Officer

Vimeo and the European Film Academy Partner to Celebrate Filmmakers and Bring "Staff Picks" Content to an All-New Audience

Vimeo to Report Q3 2024 Earnings and Host Earnings Video Event on November 4, 2024

Vimeo Delivers Spatial App Experience Built for Apple Vision Pro Enabling Users to View, Upload, and Share Spatial Videos

Vimeo Q3 2024 Shareholder Letter Available on Company's IR Site

Angi

Bumble

BuzzFeed

Cars.com

DHI Group

EverQuote

FuboTV

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

36Kr Holdings Inc. - American Depositary Shares

36KR Holdings

MediaAlpha

Hello Group Inc. - American Depositary Shares

Hello Gr

Outbrain

PropertyGuru Group Limited Ordinary Shares

PropertyGuru Group

PSQ Holdings

QuinStreet

Shutterstock

So-Young International Inc. - American Depository Shares

So-Young Intl

Taboola.com

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Vtex

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Yalla Group

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Zhihu

ZipRecruiter

TD Cowen

Piper Sandler

Truist Securities

Jefferies

Wells Fargo

Vimeo shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance above estimates.

Comments

Vimeo

Vimeo (VMEO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL